



FORM B

1.	Name of the Company	Kopran Limited
2.	Annual Financial Statement for the year ended	31 st March, 2014
3.	Type of Audit Qualification	Except for the effect of the matter described in the basis for qualified opinion paragraph
4.	Frequency of Qualification	Since Financial Year 2005-2006
	Note No.31 in Notes forming part of Accounts for the year ended 31 st March, 2014	Attention is invited to Note 31 to the financial statements regarding the investment and advances aggregating to Rs.500.61 lacs and Rs.4729.02 lacs respectively, given to subsidiary company, Kopran Research Laboratories Limited, whose accumulated losses have exceeded the networth. No Provision for investments and doubtful advances has been made by the management of the company. Consequently, the effect, if any, on the carrying value of investment and advances given cannot be ascertained. Our audit report on the financial statement for the year ended 31st March, 2013 contained a similar modification. <u>Management Response:</u> The Company has made an investment of Rs.5,00,60,750/- and has also advanced a sum of Rs.47,29,01,907/- to Kopran Research Laboratories Ltd.(KRLL), a wholly owned subsidiary of the company, for research and development (R & D) activities. The accumulated losses of KRLL has exceeded its paid up capital and reserves. The said subsidiary has been awarded numerous patents in India and abroad for its novel Anti-Ulcer molecule KNC-6 and other molecule KNC-1206. KRLL has also developed enteric coating technology and has also been awarded Indian Patent for novel process of synthesis of Rofecoxib and Sildenafil Citrate. KRLL has, vide an agreement, agreed to give the company the right to exploit the patents, intellectual properties and all rights appurtenant thereto in any manner so as to recover the dues-current and future. Considering that the investments are strategic and for long term the provision for diminution in value has not been considered necessary by the management.
	Additional comments from the Board/Audit Committee Chair	The investment in the wholly owned subsidiary, Kopran Research Laboratories Limited is long term and for strategic reason.
5.	To be signed by - CEO/Managing Director	

	CFO	----
	Auditor of the company	
	Audit Committee Chairman	